Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

This Government Contract opportunity from Department Of Health And Human Services was posted on April 1, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Wet Biosensor Chiplet Fabrication

Closed
Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 334510
New
Federal
6515--ForeSite SS Tablet w/Pressure Mapping Sensor System
Solicitation # 36C24827Q0082
The Department of Veterans Affairs, through Network Contracting Office 8, is conducting market research via a Sources Sought Notice to identify authorized sources for the ForeSite SS Tablet Pressure Mapping System manufactured by ForeSite Medical. This effort is for acquisition planning purposes and is not a formal solicitation. The required system is intended for clinical pressure assessment and treatment and must include the tablet platform, pressure-mapping sensors, sensor packs, chargers, software licenses, cables, and all necessary accessories. Key functional requirements include real-time pressure analysis and visualization, patient data storage and reporting, wireless and wired connectivity, and portable battery-powered operation. All equipment must be new and include the manufacturer's standard warranty. Interested vendors must submit electronic responses in PDF or Word format by October 30, 2026. Submissions must include the company name, address, Unique Entity Identifier, point of contact, and business size or socioeconomic status, such as SDVOSB, VOSB, Small Business, or Large Business. Additionally, respondents must provide documentation proving they are authorized to distribute or resell the ForeSite system, an estimated delivery lead time, and confirmation regarding the new condition and warranty of the product. The place of performance is located in Tampa, Florida, under NAICS code 334510.
248-NETWORK Contract Office 8 (36C248)

POSTED

1 day ago

DEADLINE

in 2 days
NAICS: 334510
New
Federal
Ocular Scanner
Solicitation # W91CRB-26-AWSP-Scanner-Ultrasonic-Ocular-RPP
The Portfolio Acquisition Executive Maneuver Ground Project Manager Maneuver Medical Systems is soliciting prototype proposals for a Scanner Ultrasonic Ocular device under Other Transaction Authority pursuant to 10 U.S.C. 4022. The objective is to award two prototype agreements for the delivery and demonstration of FDA-approved commercial solutions that provide anatomical visualization and diagnostic imaging of the eye, specifically for the anterior and posterior segments. Awardees are required to deliver four prototype units within 45 to 60 days of award for operational and environmental testing conducted in accordance with MIL-STD-810H. The estimated period of performance is twelve months, with awards expected around the first quarter of fiscal year 2027. The procurement utilizes a comparative best-value methodology, prioritizing technical approach, performance compliance, reliability, schedule realism, and past performance over cost. Key requirements include Trade Agreements Act compliance, MIL-STD-130N marking for hardware, and the provision of ruggedized transport cases. Deliverables encompass the hardware units, comprehensive user and maintenance manuals, cybersecurity documentation, and on-site operator training. Proposals must be submitted as four separate PDF volumes via DoD SAFE or secure email by November 12, 2026. This action is a direct Other Transaction Agreement and is not subject to the Federal Acquisition Regulation or Defense Federal Acquisition Regulation Supplement.
W6QK Acc-Apg

POSTED

1 day ago

DEADLINE

in 15 days
NAICS: 334510
New
Federal
Electro-Therapeutic Modalities for Pain Management (ETMPM) - Transcutaneous Electrical Nerve Stimulation (TENS) Procurement Program
Solicitation # 36C79126R0011
The Department of Veterans Affairs is soliciting proposals under Solicitation Number 36C79126R0011 to establish multiple single-award, Firm-Fixed-Price, Indefinite Delivery/Indefinite Quantity (IDIQ) base contracts for the Electro-Therapeutic Modalities for Pain Management (ETMPM) and Transcutaneous Electrical Nerve Stimulation (TENS) Procurement Program. This national program provides FDA-cleared electro-therapeutic devices and accessories to support non-opioid pain management across 168 VA Medical Centers and over 1,000 Community-Based Outpatient Clinics. The scope includes portable TENS units, portable Interferential Current (IFC) devices, thermal and non-thermal Short-Wave Diathermy (SWD) devices, and portable neuromodulation systems for headache disorders, along with associated consumables such as electrodes and lead wires. The procurement utilizes a VA Tiered Set-Aside Evaluation Approach, prioritizing Service-Disabled Veteran-Owned Small Businesses (Tier 1), followed by Veteran-Owned Small Businesses (Tier 2), other small business concerns (Tier 3), and finally other-than-small business concerns (Tier 4). Evaluation methodologies vary by item: CLINs X001 through X004 are awarded based on Lowest Price Technically Acceptable (LPTA) procedures, while CLIN X005 is evaluated using a Best-Value Tradeoff method, weighting technical factors at 60 percent, price at 25 percent, and past performance at 15 percent. Responsive proposals must include a signed SF 1449, a Technical Capability Statement, FDA 510(k) clearance letters, and three past performance documents. Non-manufacturers must provide OEM-issued Authorized Distributor Letters. Mandatory certifications include the Price Matrix (Attachment 0001), Limitations on Subcontracting (Attachment 0003), and either the Buy American Certificate (Attachment 0004) for small businesses or the Trade Agreements Certificate (Attachment 0005) for large businesses. Product samples for every offered CLIN/SLIN must be shipped to the Denver Logistics Service facility. Following several amendments, the final deadline for the receipt of all proposal documentation and product samples is November 2, 2026, at 12:00 PM CDT.
Commodities & Services Acquisition Service (36C791)

POSTED

2 days ago

DEADLINE

in 5 days

AI Contract Overview

Show more

The contract involves the design and fabrication of bioactive chiplets intended to detect physiological and biochemical signals within living organisms. These chiplets must have a functional interface compatible with dry chiplets and maintain stability within biological environments, ensuring reliable in vivo performance. The scope emphasizes advanced biosensor technology development to enable precise monitoring of biological processes. This subcontract is issued by the Advanced Research Projects Agency for Health (ARPA-H), under the Department of Health and Human Services, and is categorized under the NAICS code 334510, which relates to semiconductor and other electronic component manufacturing. The solicitation was posted on April 1, 2026, with a response deadline of May 13, 2026. While details about the location of performance or specific points of contact are not provided, the contract clearly targets innovation at the intersection of bioengineering and electronics to support health-related research and applications.

General Info

Design and fabrication of bioactive chiplets for in vivo physiological and biochemical signal detection.

NAICS

334510 - Electromedical and Electrotherapeutic Apparatus Manufacturing

Place of Performance

DC, USA

Set-Aside

NONE

Documents

This scope was carved out of ARPA-H-SOL-26-153.

The full solicitation package (16 documents), including the RFP, is on the prime solicitation, not on this scope.

View the prime solicitation

Delphi

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseClosed
Posted

subcontract

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Get full access to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → Advanced Research Projects Agency For Health (arpa-h)
ContactsNo contacts available
OfficeN/A
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
Design and fabrication of bioactive chiplets capable of detecting physiological and biochemical signals in vivo, with functional interface to dry chiplets and stability in biological environments.

More opportunities from Department Of Health And Human Services → Advanced Research Projects Agency For Health (arpa-h)

Same awarding agency

NAICS: 541714
New
Federal
ARPA-H Emerging Health Innovators (EHI) Initiative
Solicitation # ARPA-H-SOL-26-150
The Advanced Research Projects Agency for Health (ARPA-H) Emerging Health Innovators (EHI) initiative, solicitation ARPA-H-SOL-26-150, seeks to identify and engage early-career investigators to develop cutting-edge biomedical, health, and community-engaged research. This opportunity is open to researchers from academic, nonprofit, and industry organizations, provided the Principal Investigator is within eight years of completing their first terminal degree. The initiative covers 16 specific topic areas, including AI in life sciences, brain stimulation, and human tissue platforms. Awards are issued as Other Transaction (OT) agreements, which are not subject to the Federal Acquisition Regulation (FAR). The selection process is a two-step submission involving an initial anonymized Solution Summary and a subsequent Full Proposal for selected candidates. Successful awards have a total value not to exceed 1,050,000 dollars over a three-year period, consisting of a 24-month base period capped at 700,000 dollars and an optional 12-month Director's Award period capped at 350,000 dollars. Payments are structured as fixed payments triggered by the completion of 12 discrete, measurable milestones. Full proposals are evaluated based on technical merit, innovativeness, feasibility, alignment with the ARPA-H mission to accelerate health outcomes, and price reasonableness. Administrative requirements include mandatory registration in SAM.gov and the use of the ARPA-H Solutions site for all submissions. Proposers must adhere to strict formatting templates for technical and management proposals, milestone schedules, and national policy requirements, including disclosures regarding organizational conflicts of interest and research security. Performance is monitored through a formal inspection and acceptance process where the government reviews deliverables within 14 calendar days. The tentative award start date is June 30, 2027, with full proposals due by February 10, 2027.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

6 days ago

DEADLINE

in 4 months
View Details
NAICS: 541715
Federal
Fast Assessment of Solutions, Therapeutics, Pharmaceuticals, and SupplieS (FASTPASS) Innovative Solutions Opening
Solicitation # ARPA-H-SOL-26-160
The Fast Assessment of Solutions, Therapeutics, Pharmaceuticals, and Supplies (FASTPASS) program, under solicitation ARPA-H-SOL-26-160, is an initiative by the Advanced Research Projects Agency for Health (ARPA-H) to develop a near real-time, non-destructive, AI-enabled screening system. The goal is to identify contamination, adulteration, and quality defects in pharmaceutical products through their packaging at ports of entry and other supply-chain nodes using multi-modal sensing and data fusion. This 54-month program is structured into three 18-month phases, culminating in a fieldable platform with validated training materials and integrated documentation capabilities. This procurement is conducted as a multiple-award Other Transaction (OT) Agreement rather than a standard federal contract, meaning it is governed by specific OT articles instead of the Federal Acquisition Regulation. Awards are based on the most advantageous proposals, with primary evaluation factors including innovation, soundness, execution planning, risk management, and team expertise. Payments are fixed and triggered by the successful completion of milestones, managed through the Payment Management System. Proposers must be registered in SAM.gov and provide detailed technical and cost proposals, including a milestone payment schedule and research security disclosures. Amendment 01 specifically updated the cost proposal narrative model and workbook to correct typographical errors and rename appendices.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

7 days ago

DEADLINE

in 13 days
View Details
NAICS: 541714
Federal
Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS)
Solicitation # ARPA-H-SOL-26-164
The Advanced Research Projects Agency for Health (ARPA-H) is soliciting proposals for the Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS) program under solicitation ARPA-H-SOL-26-164. This five-year initiative aims to create a reusable blueprint for future adaptive seamless platform trials through the integration of three technical areas: a Phaseless Design Engine, Continuous Inference, and Agentic Operations. The program is divided into two stages, with Stage I focusing on capability buildout, FDA engagement, and the onboarding of at least three intervention arms over 24 months, followed by a 36-month Stage II dedicated to validation and deployment. A critical go/no-go milestone is obtaining FDA authorization for the platform Master Protocol IND and at least one investigational arm by the end of Stage I. The government intends to make multiple awards via Other Transaction Agreements to proposers offering the most advantageous solutions based on innovation, feasibility, and technical merit at reasonable prices. Eligible entities must possess a Unique Entity Identifier and active SAM registration. Proposals are submitted in a phased approach, beginning with a Solution Summary and potentially progressing to a Solution Pitch package. Performance will be measured by the successful integration of the three technical areas and the achievement of specific program metrics. All work must adhere to ICH E6(R3) Good Clinical Practice and strict regulatory standards to ensure inspection readiness and participant safety.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

28 days ago

DEADLINE

in about 1 month
View Details
NAICS: 541714
Federal
UNifying Imaging with QUantum Entanglement (UNIQUE) Innovative Solutions Opening (ISO)
Solicitation # ARPA-H-SOL-26-162
The Advanced Research Projects Agency for Health (ARPA-H) is seeking innovative solutions through the UNifying Imaging with QUantum Entanglement (UNIQUE) program, solicitation number ARPA-H-SOL-26-162. This 18-month, two-phase initiative aims to develop a new biomedical imaging paradigm by integrating anatomical, functional, and molecular data using quantum-derived observables and entangled 511 keV photon pairs. The scope is divided into two technical areas: the Imaging Core, which focuses on physical systems for generating and measuring quantum observables, and the Computational Foundation, which focuses on AI-driven reconstruction and multimodal data fusion. ARPA-H anticipates awarding multiple Other Transaction Agreements to eligible universities, non-profit organizations, and businesses. The submission process is two-staged, requiring Solution Summaries by late October 2026 and Full Proposals by December 15, 2026. Full proposals must consist of three volumes covering technical and management plans, cost proposals, and administrative requirements. Evaluation is based on technical innovation and feasibility, proposer expertise, potential to transform biomedicine, and cost reasonableness. Notably, for-profit organizations that are not small businesses under NAICS 541714 are required to provide a meaningful cost share. All participants must adhere to strict HHS regulations regarding human stem cell research and prohibitions on dangerous gain-of-function research and funding for foreign entities in countries of concern.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

about 1 month ago

DEADLINE

in about 2 months
View Details

Earlier notices in this NAICS code

Posted before this notice, open and closed

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS